Improving Outcomes in Patients With Cervical Cancer: How Screening, Detection, and Clinical Advances Are Making a Difference
August 17, 2015•25 min
Host: Bradley J. Monk, MD, FACS, FACOG Until 2014, chemotherapy was the only treatment option available for patients with persistent, recurrent, or metastatic disease. However, treatment with the anti–vascular endothelial growth factor (VEGF) agent, bevacizumab, in combination with paclitaxel and cisplatin or paclitaxel and topotecan was granted approval by the US Food and Drug Administration (FDA) for the treatment of this patient population in August 2014. Please join Dr. Bradley J. Monk, Professor and Director in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, as he discusses detection, screening, prevention, current treatment options, and recent and emerging data using targeted therapy for the treatment of cervical cancer.